Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HPFS DISCUSSION -- Ignore unavailable to you. Want to Upgrade?

To: Soccrates who wrote (2)	2/13/1999 7:55:00 PM
From: David Sirk	Read Replies (1) \| Respond to of 21

MORE DD Return to Disease Category Listing Additional resources in this illness area Trial Information Summary: A study on treatment for HIV. An ongoing 48 week medical research study involving MKC-442, a new Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), in combination with Viracept, a Protease Inhibitor, and two Nucleoside Reverse Transcriptase Inhibitors (NRTIs). The goal is to determine if MKC-442 plus Viracept results in a better reduction in HIV-1 RNA compared with Viracept with either d4T+3TC or d4T+ddI. After initial screen and baseline visits, study visits are conducted monthly for 6 months, then every 2 months until study completion. All study medication will be provided free of charge while participating in the study and HIV-1 PCR results will be provided in real time. Patient/Inclusion/Exclusion Criteria: HIV infected with a recent plasma HIV-1 RNA 10,000 copies per ml or greater Currently receiving dual treatment with two NRTIs (AZT, 3TC, ddI and/or d4T) for greater than 16 weeks Willing and able to switch NRTI therapy to either d4T+3TC or d4T+ddI, based upon patient and physician reference Naive to Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors Only subjects who meet the above criteria should contact the site for further information. Contact: Sandra Cassarella, R.N. CSI / Paul J. Cimoch, M.D. 100 Pacifica, Suite 100 Irvine, CA 92618 Telephone: 949-753-0670 Fax: 949-753-0924 Email: sandcas@earthlink.net